Marcel R.M. van den Brink, MD, PhD, from Memorial Sloan Kettering Cancer Center, describes a novel CLIA-certified next-generation sequencing-based assay for hematologic malignancies.
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan Kettering Cancer Center, describes a novel CLIA-certified next-generation sequencing-based assay for hematologic malignancies. The analysis of the assay was presented at the 2013 ASH Annual Meeting. Information below reflects that of which was published in the abstract prior to the meeting.
View the full abstract > >
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen